News | 16 October 2025
Nouryon launches sustainable technologies for cleaning ingredient at SEPAWA Congress
This new suite of products demonstrates Nouryon’s leadership in cleaning ingredient solutions
This new suite of products demonstrates Nouryon’s leadership in cleaning ingredient solutions
Acquisition aims to strengthen Merck's downstream process offering of advanced filtration and chromatography solutions
The new plant will manufacture high-quality Type I borosilicate glass tubing
This innovation reinforces Fredun's commitment to creating a 360 degree pet wellness ecosystem
Cadila Pharmaceuticals has introduced Dlorfast-M-Tablets as a dual-action therapy that targets two key pathways of allergic response
Acquisition includes OTX-201, an investigational next-generation CAR T-cell therapy designed to reprogram cells in vivo with potential best-in-class profile for autoimmune diseases
ExellenS applies optimized facility designs, equipment, and processes across all sites to ensure equivalency and speed
Acquisition expands Novo Nordisk’s leadership in obesity-related comorbidities and metabolic diseases
The Court dismissed Swiss drugmaker Roche’s plea for interim injunction
First patients enrolled in Phase I trial with KQB548, an investigational KRAS inhibitor designed to treat KRAS G12D-mutated tumors
Facility marks cornerstone of $50 billion investment in medicines R&D and manufacturing in America
New gene expression profiling test enhances precision in assessing lung transplant rejection and injury
The new line features advanced isolator technology to deliver enhanced sterility assurance, throughput and operational precision
New filling line approval supports delivery of integrated, end-to-end solutions across the entire biologics and bioconjugates value chain
Lilly's Omvoh is the first and only IL-23p19 antagonist to show four years of sustained, corticosteroid-free comprehensive patient outcomes in ulcerative colitis
Lupin's partnership program is designed to foster collaborations with companies looking to extend their product lifecycles
Panacea Biotec receives acceptance from CMSS for supply of bOPV
RedHill will receive $500,000 in guaranteed payments, including a $250,000 upfront payment and $250,000 in fixed payments due within 18 months
The collaboration combines the extensive CMC expertise of Sai Life Sciences in API development, Agility Life Sciences in formulation development, and Centrix Pharma Solutions in drug product development and clinical manufacturing
Positive volume growth was observed in key therapies such as respiratory (13.2% yoy), anti-neoplastics (12.1% yoy) and cardiac (4.8% yoy) during September 2025
Subscribe To Our Newsletter & Stay Updated
